Artal Group’s ProQR Therapeutics PRQR Stock Holding History

Artal Group’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,196,218	Closed	-$5.02M	–	161
2020 Q4	$5.02M	Hold	1,196,218	–	–	0.11%	108
2020 Q3	$5.73M	Sell	1,196,218 -62,959	-5%	-$329K	0.14%	92
2020 Q2	$7.66M	Sell	1,259,177 -40,823	-3%	-$221K	0.21%	84
2020 Q1	$7.14M	Hold	1,300,000	–	–	0.3%	58
2019 Q4	$12.9M	Hold	1,300,000	–	–	0.5%	36
2019 Q3	$7.49M	Hold	1,300,000	–	–	0.3%	59
2019 Q2	$11.8M	Sell	1,300,000 -100,000	-7%	-$1.18M	0.48%	45
2019 Q1	$19.4M	Hold	1,400,000	–	–	0.79%	30
2018 Q4	$22.1M	Buy	1,400,000 +100,000	+8%	+$1.84M	0.82%	26
2018 Q3	$25.2M	Sell	1,300,000 -200,000	-13%	-$2.13M	0.65%	24
2018 Q2	$10.9M	Sell	1,500,000 -400,000	-21%	-$2.02M	0.23%	44
2018 Q1	$5.84M	Hold	1,900,000	–	–	0.07%	64
2017 Q4	$6.13M	Buy	1,900,000 +400,000	+27%	+$1.44M	0.09%	63
2017 Q3	$7.28M	Buy	1,500,000 +1,000,000	+200%	+$5.19M	0.13%	53
2017 Q2	$2.6M	Buy	500,000 +100,000	+25%	+$497K	0.05%	87
2017 Q1	$2M	Buy	+400,000	New	+$1.76M	0.04%	83

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Artal Group's PRQR Position: Q1 2021 in Review

Artal Group sold out of ProQR Therapeutics (PRQR) in Q1 2021, closing a stake of 1,196,218 shares — an estimated $5.02M sold.

Artal Group first reported a position in PRQR in Q1 2017 and held it in 16 quarters. The position peaked at $25.2M in Q3 2018. 64 funds tracked by Wall St. Rank hold PRQR as of Q1 2021.

Artal Group reported no remaining ProQR Therapeutics position as of Q1 2021 after selling out during the quarter.
Artal Group sold 1,196,218 ProQR Therapeutics shares in Q1 2021, an estimated $5.02M.
Artal Group first reported a position in ProQR Therapeutics in Q1 2017 and held it in 16 quarters.
Artal Group's ProQR Therapeutics position peaked at $25.2M in Q3 2018.
64 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2021.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.